Tenaya Therapeutics (TNYA) Reports Positive Interim Data for Gene Therapy TN-401 in ARVC Trial
Tenaya Therapeutics (TNYA) disclosed positive interim Phase 1b/2 data for TN-401 in PKP2-associated ARVC, showing increased protein expression and reduced arrhythmias.